Inflammation imaging of atherosclerosis in Apo-E-deficient mice using a 99mTc-labeled dual-domain cytokine ligand

Nuclear Medicine and Biology

Volumn 41, Issue 10, 2014, Pages 785-792

  Liu, Zhonglin ^a   Lerman, Lilach O ^b   Tang, Hui ^b   Barber, Christy ^a   Wan, Li ^a   Hui, Mizhou M ^c   Furenlid, Lars R ^a   Woolfenden, James M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c NONE   (United States)

Author keywords

Apolipoprotein E deficient mice; Atherosclerosis; Inflammation; Interleukin 1; SPECT; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; RADIOLIGAND; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2 FC; TUMOR NECROSIS FACTOR RECEPTOR 2 FC INTERLEUKIN 1 RECEPTOR BLOCKING AGENT TC 99M; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; TECHNETIUM COMPLEX; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; CONTROLLED STUDY; HYPERLIPOPROTEINEMIA TYPE 3; IN VIVO STUDY; INFLAMMATION; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; RADIOACTIVITY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; C57BL MOUSE; COMPLICATION; DIAGNOSTIC USE; FEMALE; IMAGE PROCESSING; KNOCKOUT MOUSE; METABOLISM; MOLECULAR IMAGING; PHYSIOLOGY; PROCEDURES;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR IMAGING; ORGANOTECHNETIUM COMPOUNDS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84912080920     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.08.004     Document Type: Article

References (26)

1. ten Kate G.L., Sijbrands E.J., Staub D., Coll B., ten Cate F.J., Feinstein S.B., et al. Noninvasive imaging of the vulnerable atherosclerotic plaque. Curr Probl Cardiol 2010, 35:556-591.
2. Kaufmann B.A., Carr C.L., Belcik J.T., Xie A., Yue Q., Chadderdon S., et al. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arterioscler Thromb Vasc Biol 2010, 30:54-59.
3. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281-291.
4. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79:360-376.
5. Cain B.S., Meldrum D.R., Dinarello C.A., Meng X., Joo K.S., Banerjee A., et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999, 27:1309-1318.
6. Kan H., Xie Z., Finkel M.S. TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. Am J Physiol 1999, 277:H1641-H1646.
7. Bendele A.M., Chlipala E.S., Scherrer J., Frazier J., Sennello G., Rich W.J., et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000, 43:2648-2659.
8. Xie B., Liu S., Wu S., Chang A., Jin W., Guo Z., et al. A novel bifunctional protein TNFR2-Fc-IL-1ra (TFI): expression, purification and its neutralization activity of inflammatory factors. Mol Biotechnol 2013, 54:141-147.
9. 99mTc-labeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways. Nucl Med Biol 2012, 39:905-915.
10. 99mTc-labeled dual-domain cytokine ligand. J Nucl Med 2013, 54:2139-2145.
11. Blankenberg F.G., Vanderheyden J.L., Strauss H.W., Tait J.F. Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis. Nat Protoc 2006, 1:108-110.
12. 99mTc-labeled dual-domain cytokine ligand for imaging of inflammation. Nucl Med Biol 2011, 38:795-805.
13. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2006, 33:117-126.
14. Olofsson P.S., Sheikine Y., Jatta K., Ghaderi M., Samnegard A., Eriksson P., et al. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 2009, 73:1531-1536.
15. Merhi-Soussi F., Kwak B.R., Magne D., Chadjichristos C., Berti M., Pelli G., et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005, 66:583-593.
16. Shemesh S., Kamari Y., Shaish A., Olteanu S., Kandel-Kfir M., Almog T., et al. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice. Atherosclerosis 2012, 222:329-336.
17. Efthimiou P., Markenson J.A. Role of biological agents in immune-mediated inflammatory diseases. South Med J 2005, 98:192-204.
18. Vilcek J., Lee T.H. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991, 266:7313-7316.
19. Popa C., Netea M.G., van Riel P.L., van der Meer J.W., Stalenhoef A.F. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007, 48:751-762.
20. Lamon B.D., Hajjar D.P. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol 2008, 173:1253-1264.
21. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992, 89:4845-4849.
22. Fernandez-Botran R., Crespo F.A., Sun X. Soluble cytokine receptors in biological therapy. Expert Opin Biol Ther 2002, 2:585-605.
23. Bradley J.R. TNF-mediated inflammatory disease. J Pathol 2008, 214:149-160.
24. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002, 14:477-492.
25. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
26. Daugherty A. Mouse models of atherosclerosis. Am J Med Sci 2002, 323:3-10.